Chenglong Xu

State Key Laboratory Of Radio Frequency Heterogeneous Integration
Shenzhen, 518060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

RbLa(SO4)2: A KBBF-like Deep-UV Transparent Rare Earth Sulfate with Strong SHG Response and High Thermal Stability Enabled by Multicomponent Structural Design.

RbLa(SO4)2: A KBBF-like Deep-UV Transparent Rare Earth Sulfate with Strong SHG Response and High Thermal Stability Enabled by Multicomponent Structural Design.

Journal: Inorganic chemistry

Published: February 02, 2026

Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo.

Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo.

Journal: Bioorganic chemistry

Published: November 27, 2025

Discovery of the first dual PD-L1/JAK inhibitor with enhanced in vivo antitumor immunity.

Discovery of the first dual PD-L1/JAK inhibitor with enhanced in vivo antitumor immunity.

Journal: European journal of medicinal chemistry

Published: October 16, 2025

Discovery of novel quinazoline analogs as tubulin inhibitors targeting the colchicine binding site for potent antitumor therapy in combination with PD-L1 inhibitors.

Discovery of novel quinazoline analogs as tubulin inhibitors targeting the colchicine binding site for potent antitumor therapy in combination with PD-L1 inhibitors.

Journal: Bioorganic chemistry

Published: September 01, 2025

Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8+ Effector T‑Cell Function for Synergistic Cancer Immunotherapy.

Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8+ Effector T‑Cell Function for Synergistic Cancer Immunotherapy.

Journal: ACS central science

Published: May 06, 2025

Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy.

Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy.

Journal: Journal of medicinal chemistry

Published: April 15, 2025

Discovery of Novel Hydrazide-Based HDAC3 Inhibitors as Epigenetic Immunomodulators for Cancer Immunotherapy.

Discovery of Novel Hydrazide-Based HDAC3 Inhibitors as Epigenetic Immunomodulators for Cancer Immunotherapy.

Journal: Journal of medicinal chemistry

Published: January 23, 2025

Discovery of novel Bis-amide analogue ST12 for the treatment of inflammatory bowel diseases (IBD) by inhibiting NLRP3 inflammasome activation.

Discovery of novel Bis-amide analogue ST12 for the treatment of inflammatory bowel diseases (IBD) by inhibiting NLRP3 inflammasome activation.

Journal: Bioorganic chemistry

Published: November 28, 2024

Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects.

Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects.

Journal: Journal of medicinal chemistry

Published: July 20, 2024

Corrigendum to "Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity" [Bioorgan. Chem. 117 (2021) 105447].

Corrigendum to "Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity" [Bioorgan. Chem. 117 (2021) 105447].

Journal: Bioorganic chemistry

Published: July 10, 2024

Discovery of novel thiophene[3,2-d]pyrimidine-based tubulin inhibitors with enhanced antitumor efficacy for combined use with anti-pd-l1 immunotherapy in melanoma.

Discovery of novel thiophene[3,2-d]pyrimidine-based tubulin inhibitors with enhanced antitumor efficacy for combined use with anti-pd-l1 immunotherapy in melanoma.

Journal: European journal of medicinal chemistry

Published: June 28, 2024

Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.

Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.

Journal: Bioorganic chemistry

Published: January 29, 2024

Showing 1-12 of 16

Last Updated: 09/26/2026